Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Heart and Vessels
Erschienen in:

23.03.2020 | Original Article

Elevated chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes was observed in the patient of atrial fibrillation

verfasst von: Keisuke Okamura, Tetsu Okuda, Yosuke Takamiya, Kazuyuki Shirai, Hidenori Urata

Erschienen in: Heart and Vessels | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Chymase is an angiotensin II-forming serine proteinase and elevation of its tissue activity occurs in various cardiovascular diseases. Several authors have suggested that there is an association between the renin–angiotensin system and atrial fibrillation (AF). Chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes (CML chymase dAIIFA) was investigated in patients with AF and patients in sinus rhythm. Consecutive outpatients were recruited at our hospital. CML chymase dAIIFA was measured using a Nma/Dnp-type fluorescence-quenching substrate of modified angiotensin I in the presence or absence of a specific serine proteinase inhibitor. To search the independent contributing factor of existence of AF, the analysis between groups was carried out using multivariate analysis after univariate analysis. The patients were classified into a sinus rhythm (SR) group (n = 459) or an AF group (n = 48). CML chymase dAIIFA was significantly higher in the AF group (622 pmol/min/mg) compared with the SR group (488 pmol/min/mg) (p < 0.001). Logistic regression analysis revealed that high CML chymase dAIIFA was an independent determinant of the existence of AF (p < 0.001). Elevation of CML chymase dAIIFA was associated with AF. Activation of chymase might be linked to atrial structural and electrical remodeling.
Literatur
1.
Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, Aizawa Y, Yamashita T, Atarashi H, Horie M, Ohe T, Doi Y, Shimizu A, Chishaki A, Saikawa T, Yano K, Kitabatake A, Mitamura H, Kodama I, Kamakura S (2009) Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 137:102–107PubMed
2.
Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X (2013) Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 112:1142–1147PubMed
3.
Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946–952PubMed
4.
Koitabashi T, Inomata T, Niwano S, Nishii M, Takeuchi I, Nakano H, Shinagawa H, Takehana H, Izumi T (2005) Paroxysmal atrial fibrillation coincident with cardiac decompensation is a predictor of poor prognosis in chronic heart failure. Circ J 69:823–830PubMed
5.
Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886–2891PubMed
6.
Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006–3010PubMed
7.
Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U (2000) Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35:1669–1677PubMed
8.
Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K (2000) Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101:2612–2617PubMed
9.
Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K (2003) Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41:2197–2204PubMed
10.
Nakashima H, Kumagai K (2007) Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 71:1977–1982PubMed
11.
Yamashita T, Sekiguchi A, Kato T, Tsuneda T, Iwasaki YK, Sagara K, Iinuma H, Sawada H, Aizawa T (2007) Angiotensin type 1 receptor blockade prevents endocardial dysfunction of rapidly paced atria in rats. J Renin Angiotensin Aldosterone Syst 8:127–132PubMed
12.
Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:2926–2931PubMed
13.
Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN, Val-He FTI (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149:548–557PubMed
14.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S, Investigators C (2006) Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 152:86–92PubMed
15.
Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:1832–1839PubMed
16.
Investigators G-A, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617
17.
Investigators ACTIVEI, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ (2011) Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928–938
18.
Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T (2012) Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 5:43–51
19.
Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, Investigators JRI (2011) Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 13:473–479PubMed
20.
Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, Derosa G (2012) Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther 17:34–43PubMed
21.
Arakawa K (1996) Serine protease angiotensin II systems. J Hypertens Suppl 14:S3–7PubMed
22.
Wei CC, Meng QC, Palmer R, Hageman GR, Durand J, Bradley WE, Farrell DM, Hankes GH, Oparil S, Dell'Italia LJ (1999) Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 99:2583–2589PubMed
23.
Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, Miyazaki M (2001) Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 305:191–195PubMed
24.
Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A (1990) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265:22348–22357PubMed
25.
Urata H, Healy B, Stewart RW, Bumpus FM, Husain A (1990) Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 66:883–890PubMed
26.
Ihara M, Urata H, Shirai K, Ideishi M, Hoshino F, Suzumiya J, Kikuchi M, Arakawa K (2000) High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology 94:247–253PubMed
27.
Koga T, Urata H, Inoue Y, Hoshino T, Okamoto T, Matsunaga A, Suzuki M, Miyazaki J, Ideishi M, Arakawa K, Saku K (2003) Human chymase expression in a mice induces mild hypertension with left ventricular hypertrophy. Hypertens Res 26:759–768PubMed
28.
Hoshino F, Urata H, Inoue Y, Saito Y, Yahiro E, Ideishi M, Arakawa K, Saku K (2003) Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 41(Suppl 1):S11–18PubMed
29.
Okamura K, Okuda T, Shirai K, Urata H (2018) Positive correlation between blood pressure or heart rate and chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes measured by new ELISA. Clin Exp Hypertens 40:112–117PubMed
30.
Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE (1990) Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 82:792–797PubMed
31.
Flaker GC, Fletcher KA, Rothbart RM, Halperin JL, Hart RG (1995) Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am J Cardiol 76:355–358PubMed
32.
Takai S, Jin D, Sakaguchi M, Miyazaki M (1999) Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 100:654–658PubMed
33.
Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K (1998) Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 32:514–520PubMed
34.
Murakami K, Uehara Y, Abe S, Inoue Y, Ideishi M, Saku K, Urata H (2007) Positive correlation between chymase-like angiotensin II-forming activity in mononuclear cells and serum cholesterol level. J Cardiol 50:291–298PubMed
35.
Sakamoto H, Okamoto E, Imataka K, Ieki K, Fujii J (1995) Prediction of early development of chronic nonrheumatic atrial fibrillation. Jpn Heart J 36:191–199PubMed
36.
Brodsky MA, Allen BJ, Capparelli EV, Luckett CR, Morton R, Henry WL (1989) Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol 63:1065–1068PubMed
37.
Dittrich HC, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicod PH (1989) Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 63:193–197PubMed
38.
Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM (2011) Chymase-dependent generation of angiotensin II from angiotensin-(1–12) in human atrial tissue. PLoS ONE 6:e28501PubMedPubMedCentral
39.
Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, Dell'italia LJ (2014) An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci (Lond) 126:461–469
40.
Nagata S, Varagic J, Kon ND, Wang H, Groban L, Simington SW, Ahmad S, Dell'Italia LJ, VonCannon JL, Deal D, Ferrario CM (2015) Differential expression of the angiotensin-(1–12)/chymase axis in human atrial tissue. Ther Adv Cardiovasc Dis 9:168–180PubMedPubMedCentral
41.
Gerdts E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, Dahlof B, Devereux RB, Losartan Intervention For Endpoint Reduction in Hypertension S (2002) Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 39:739–743PubMed
42.
Shi Y, Li D, Tardif JC, Nattel S (2002) Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 54:456–461PubMed
43.
Boldt A, Scholl A, Garbade J, Resetar ME, Mohr FW, Gummert JF, Dhein S (2006) ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 101:261–267PubMed
44.
Li Y, Li WM, Xue JY, Han W, Yang SS, Gu HY (2004) Effects of Losartan on acute atrial electrical remodeling. Chin Med J (Engl) 117:643–646
45.
Tsai CT, Lai LP, Hwang JJ, Chen WP, Chiang FT, Hsu KL, Tseng CD, Tseng YZ, Lin JL (2008) Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation. J Hypertens 26:570–582PubMed
46.
Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU (2001) Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 88(906–909):A908
47.
Devarajan S, Yahiro E, Uehara Y, Habe S, Nishiyama A, Miura S, Saku K, Urata H (2015) Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension. Am J Physiol Heart Circ Physiol 309:H1987–1996PubMed
48.
Hirota S, Sadanaga T, Mitamura H, Fukuda K, Ogawa S (2013) B-type natriuretic peptide levels are decreased by reducing dietary salt intake in patients with permanent atrial fibrillation. Int J Cardiol 167:294–296PubMed
49.
Sudoh T, Kangawa K, Minamino N, Matsuo H (1988) A new natriuretic peptide in porcine brain. Nature 332:78–81PubMed
50.
Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M (2000) Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J 64:765–771PubMed
51.
Basu R, Poglitsch M, Yogasundaram H, Thomas J, Rowe BH, Oudit GY (2017) Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. J Am Coll Cardiol 69:805–819PubMed
52.
Fujimi K, Uehara Y, Abe S, Kawamura A, Devarajan S, Miura S, Saku K, Urata H (2010) Homocysteine-induced oxidative stress upregulates chymase in mouse mastocytoma cells. Hypertens Res 33:149–154PubMed
Metadaten
Titel
Elevated chymase-dependent angiotensin II-forming activity in circulating mononuclear leukocytes was observed in the patient of atrial fibrillation
verfasst von
Keisuke Okamura
Tetsu Okuda
Yosuke Takamiya
Kazuyuki Shirai
Hidenori Urata
Publikationsdatum
23.03.2020
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 8/2020
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-020-01582-4

Weitere Artikel der Ausgabe 8/2020

A novel risk score on admission for predicting death or need for surgery in patients with acute type A intramural hematoma receiving medical therapy

  • Original Article

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation

  • Open Access
  • Original Article

Frontal QRS-T angle and left ventricular diastolic function assessed by ECG-gated SPECT in the absence of significant perfusion abnormality

  • Original Article

Patient-specific heart simulation can identify non-responders to cardiac resynchronization therapy

  • Open Access
  • Original Article

Clinical impact of statin therapy on vasospastic angina: data from a Korea nation-wide cohort study

  • Original Article

Evaluation of coronary artery disease in patients with atrial fibrillation by cardiac computed tomography for catheter ablation: CADAF-CT trial

  • Open Access
  • Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Kardiologie

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

LVAD auch bei kalt-trockener terminaler Herzinsuffizienz wirksam

Auch Personen mit kalt-trockener terminaler Herzinsuffizienz profitieren von einem linksventrikulären Unterstützungssystem (LVAD), wie Daten aus einem US-Register nahelegen. Doch es gibt Besonderheiten.     

Koronare Herzkrankheit: Das waren die Top-Studien 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise